<DOC>
	<DOCNO>NCT02317471</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness autologous gp96 treatment gastric cancer .</brief_summary>
	<brief_title>Immunotherapy Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Disease characteristic : Histologically confirm gastric carcinoma : clinical stage III ( accord Japanese gastric cancer classification ) , must undergo radical resection 2 . Able read understand inform consent document , must sign informed consent 3 . Age : 18 75 year old 4 . Availability least 0.5 g tumor sample 5 . ECOG ≤1；life expectancy &gt; =12 week , able comply studyrelated procedure 6 . Adequate bone marrow function include absence lymphopenia ( ANC &gt; 1,500/ mm3 ; Hemoglobin &gt; 10g/dL ; platelet count &gt; 100,000/mm3 ) , adequate liver function ( serum glutamic oxaloacetic transaminase/ aspartate aminotransferase [ AST ] , alanine amino transferase [ ALT ] &lt; 2.5 time institutional upper limit normal [ IULNs ] bilirubin ( total ) &lt; 1.5 time IULN ) , adequate renal function ( BUN creatinine &lt; 1.5 time IULNs ) 7 . Normal heart function 8 . NOT participate ANY clinical trial within 4 week prior vaccination . 1 . Unable get inform consent 2 . Female patient pregnant breastfeed 3 . Progression prior treatment determine principal investigator 4 . Transplant recipient 5 . Patients currently diagnose Human Immunodeficiency Virus active uncontrolled infection 6 . Unstable severe intercurrent medical condition 7 . Patient allergic constitution 8 . Patients systemic disease need treat immunosuppressant Corticosteroids .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>